Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, Inc. (NASDAQ: CRIS) announced the publication of a research paper in ACS Medicinal Chemistry Letters, detailing CA-4948, an orally bioavailable IRAK4 inhibitor for treating hematologic malignancies. This small molecule demonstrated potent IRAK4 inhibition and showed tumor regression in animal studies without significant toxicity. CA-4948 is currently in Phase 1 trials for non-Hodgkin lymphomas and acute myeloid leukemia. Curis plans to commence a combination study with ibrutinib for non-Hodgkin lymphomas this quarter. Curis emphasizes the need for additional funding to support ongoing operations.
Summary not available.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at two investor conferences on September 15, 2020. The first event is the Cantor Fitzgerald Virtual Global Healthcare Conference at 9:20 am ET, followed by the H.C. Wainwright & Co. 22nd Annual Global Investment Conference at 4:30 pm ET. Both presentations will be available via live webcast on the company's website, with replays accessible for 90 days post-event. Curis specializes in cancer therapeutics, with ongoing trials for several innovative drugs.
Curis, Inc. (NASDAQ: CRIS) reported its Q2 2020 financial results, highlighting a net loss of $6.7 million, or $0.17 per share, an improvement from a loss of $7.2 million in Q2 2019. Revenue increased to $2.4 million from $2.1 million year-over-year. The biotech firm advanced its clinical pipeline, notably the IRAK4 inhibitor CA-4948, with ongoing studies for non-Hodgkin's lymphoma and acute myeloid leukemia. FDA clearance was received for CI-8993, a new anti-VISTA antibody study. Curis expects cash to support operations through the first half of 2021.
Curis, Inc. (NASDAQ: CRIS) will announce its second quarter 2020 financial results on August 4, 2020, after US market close. A conference call is scheduled for the same day at 4:30 p.m. ET, accessible via phone or the company's website. Curis specializes in developing innovative therapeutics for cancer treatment and has ongoing collaborations focusing on immuno-oncology and precision oncology. The company holds exclusive licenses for several drug candidates currently in clinical trials.